Carolyn Starrett, senior vice president, Provider Solutions, Flatiron Health, discusses the importance of community oncologists collaborating and learning from each other to identify best practices.
Carolyn Starrett, senior vice president, Provider Solutions, Flatiron Health, discusses the importance of community oncologists collaborating and learning from each other to identify best practices.
Transcript
How important is it for community oncologists to collaborate and learn from each other and identify best practices?
We think that’s the most important thing, honestly. The reason we invest so heavily in this event [OncoCloud] every year is that we can only do so much in our offices in New York. That’s not what matters; what matters is the feedback we’re hearing from all our customers, from all the clinicians, from all the operators, from all the researchers who are out there treating patients everyday.
We really see the top goal of this event is about bringing those people together with our team, fostering the collaboration, fostering the conversations, learning about these best practices, learning what each practice is doing, so that we can spread that knowledge and help rise the tide for everyone.
This is a big investment for us; we’re still a relatively small company, but we think it pays off in spades. Every year I come I’m just consistently impressed by how many really cool conversations, new connections, new stories, new insights I learn from talking with all of our customers and practices.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More